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AbsTrACT
background and purpose The recent randomized 
trials demonstrated the benefit of mechanical 
thrombectomy in stroke therapy. however, treatment 
using different strategies is an ongoing area of 
investigation. The PrOMise study analyzed the safety 
and effectiveness of the Penumbra system with the 
ace68 and ace64 reperfusion catheters in aspiration 
thrombectomy of stroke, using a Direct aspiration First 
Pass Technique (aDaPT).
Methods PrOMise was a prospective study which 
enrolled 204 patients with intracranial anterior 
circulation large vessel occlusion (lVO) ischemic stroke 
in 20 centers from February 2016 to May 2017. initial 
treatment was with the ace68/ace64 catheters within 
6 hours of symptom onset. imaging and safety review 
was performed by an independent core laboratory and 
a clinical events committee. The primary angiographic 
outcome was revascularization to mTici 2b-3 at 
immediate post-procedure and the primary clinical 
outcome was 90-day modified rankin scale (mrs) score 
≤2. safety assessment included device- and procedure-
related serious adverse events (saes), symptomatic 
intracranial hemorrhage (sich), mortality, and 
embolization of new territory (enT).
results enrolled patients had a median age of 74 (iQr 
65–80) years and a median admission nihss of 16 (iQr 
11–20). The post-procedure mTici 2b-3 revascularization 
rate was 93.1% and the 90-day mrs 0–2 rate was 61%. 
Device- and procedure-related saes at 24 hours occurred 
in 1.5% and 3.4%, respectively, 90-day mortality was 
7.5%, sich occurred in 2.9% while enT occurred in 
1.5%.
Conclusions For frontline therapy of lVO stroke, the 
ace68/ace64 catheters for aspiration thrombectomy 
were found to be safe and showed similar efficacy 
to randomized trials using other revascularization 
techniques.
Clinical Trial registration : ncT02678169;Pre-
results.
InTroduCTIon 
Six randomized controlled trials (RCTs) estab-
lished the role of mechanical thrombectomy in 
early acute ischemic stroke (AIS):1–6 in these trials, 
most of the devices used were stent retrievers.7 
As a result of position statements recommending 
endovascular therapy,8–10 a significant growth 
in the treatment of patients with emergent large 
vessel occlusion (ELVO) has been observed and is 
expected to continue.11–13 An operational defini-
tion of ELVO to standardize the description of the 
therapeutic target for endovascular thrombectomy 
was proposed.14 Recently, several studies have 
investigated patient outcomes after advances in 
different devices and techniques, increased physi-
cian experience, and streamlined in-hospital proce-
dures for endovascular therapy.15–18 The Penumbra 
System (Penumbra, Inc., Alameda, CA) is a family 
of mechanical thrombectomy devices specifically 
designed to remove thrombus through aspiration, 
receiving 510(k) clearance from the US FDA in 
2007.19 20 THERAPY was an RCT assessing aspi-
ration thrombectomy with IV rt-PA versus IV rt-PA 
alone.21 Further developments included ADAPT (A 
Direct Aspiration First Pass Technique), a throm-
bectomy approach wherein aspiration alone is used 
to remove the occlusion, followed by adjunctive 
therapies if necessary.22–24 In addition, findings 
from the Penumbra 3D RCT, which randomized 
patients to either a frontline approach with the 3D 
stent retriever with aspiration vs aspiration alone, 
demonstrated no significant difference between 
treatment groups in the rates of modified Throm-
bolysis in Cerebral Infarction (mTICI) 2–3 revas-
cularization, 90-day modified Rankin Scale (mRS) 
0–2, symptomatic intracranial hemorrhage (sICH), 
procedure or device-related serious adverse events 
(SAEs), or mortality.25
At the time of this study’s design, the safety and 
efficacy of the ADAPT technique using ACE68/64 
catheters with the Penumbra System (PS) had not 
been assessed in a prospective study. The aim of a 
prospective, multicenter, observational, single-arm 
European Registry on the ACE reperfusion cath-
eters and the Penumbra System in the treatment 
of acute ischemic stroke (PROMISE) study was 
to address this need for real-world data on the 
safety and effectiveness of the PS with the novel 
Penumbra reperfusion catheters, ACE68/64, in 
patients with AIS from anterior circulation LVO, 
treated with the ADAPT technique. The PROMISE 
study incorporated an integrated aspiration throm-
bectomy system which includes a Penumbra aspi-
ration pump indicated for revascularization of AIS 
patients.
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MeThods
PROMISE was a prospective, multicenter, single-arm, open-label, 
observational European study to evaluate the safety and effec-
tiveness of the ACE68/64 reperfusion catheters and the PS in the 
treatment of AIS ( ClinicalTrials. gov Identifier, NCT02678169). 
Patients presenting within 6 hours from symptom onset with an 
anterior circulation LVO AIS (within the internal carotid artery 
(ICA) and internal carotid terminus, middle cerebral artery 
(MCA) – M1/M2 segments) were eligible. This study was a 
non-inferiority comparison of 90-day mRS 0–2 rates between 
the ACE Penumbra System group and the intra-arterial therapy 
(IAT) group in the MR CLEAN trial.1 At the time of study design, 
MR CLEAN established the benefit of intra-arterial therapy 
against medical management alone and was the only published 
RCT for our non-inferiority hypothesis and sample size calcula-
tion. The main aim of the study, however, was to assess the safety 
and effectiveness of the ACE68/64 in patients treated with the 
ADAPT technique. Every patient was checked for study eligi-
bility and recorded on a site-specific Screening Log.
Treatment consisted of the ADAPT technique with thrombo-as-
piration using ACE68 and ACE64 as first intention according to 
site routine practice. For rescue, any approved revascularization 
device and/or intra-arterial medication was allowed at the oper-
ators’ discretion, including non-Penumbra devices. Adjunctive 
therapy was defined as the use of a stent retriever following a 
reperfusion catheter: before adjunctive therapy, three passes of 
the ACE catheter were recommended. At the discretion of the 
clinicians in charge of the patient or the investigator, the patient 
was pretreated with intravenous thrombolytics (IV tPA), and/or 
treated under general or local anesthesia, or conscious sedation. 
Follow-up visits to assess functional outcome, quality of life, and 
adverse events took place at 24 hours, 7 to 10 days or discharge, 
30-days, and 90-days post-procedure. In Europe, the ACE68 and 
ACE64 catheters were available in 2016 and 2015, respectively.
All procedures were in accordance with national and local 
ethical and institutional guidelines and site routine clinical 
practice. The local Ethics Committees approved the study, and 
the patients or their representatives provided written informed 
consent, according to local regulations.
Imaging analysis
All imaging scans (baseline CT/MRI, pre-procedure/procedure 
DSA, and 24 hours' scan) were reviewed and adjudicated by 
an independent Core Imaging Laboratory (Toronto Western 
Hospital, University of Toronto) for mTICI and for procedural 
and safety assessments (confirmation of vessel damage and 
embolization of new territory (ENT), identification, and classifi-
cation of intracranial hemorrhages).
Patients
Patient eligibility criteria included age of at least 18 years, 
presentation with anterior circulation LVO within 6 hours of 
stroke onset or time last known to be well, occlusion of the 
internal carotid artery (ICA and ICA terminus) or MCA M1/
M2, National Institutes of Health Stroke Scale (NIHSS)≥2, and 
pre-stroke mRS score ≤2. LVO status was determined mostly 
by CTA (85.3%), with some by MRA (14.7%). Imaging eligi-
bility criteria were CT Alberta Stroke Program Early CT Score 
(ASPECTS)≥6 or MR DWI ASPECTS≥5, and absence of tandem 
extracranial occlusion or severe arterial stenosis requiring 
treatment prior to thrombectomy. Study exclusion criteria can 
be found in the Online Supplement. Up to 210 patients who 
met eligibility criteria were to be enrolled in a maximum of 25 
European investigational sites, and an exclusion log of screened 
but not enrolled patients was kept at each site.
Primary and secondary endpoints
Primary endpoints were angiographic revascularization assessed 
by digital subtraction angiography of the occluded target 
vessel to mTICI 2b or 3 at immediate post-procedure as adju-
dicated by an independent Core Laboratory and functional 
independence (mRS 0–2) at 90 days by mRS certified medical 
personnel, without blinding to the clinical or radiological patient 
data. Secondary endpoints were any device- and procedure-re-
lated SAEs at 24 hours' and 30 days' post-procedure, all-cause 
morbidity (defined as mRS 3–5) and mortality at 90 days, occur-
rence of ENT, occurrence of sICH at 24 hours, and occurrence 
of vessel damage at the end of the ADAPT procedure. Safety 
was assessed by collecting adverse events data during all study 
visits. Hemorrhagic transformation was radiologically clas-
sified according to the European Cooperative Acute Stroke 
Study (ECASS) definitions. sICH was defined according to 
ECASS-II definition26 27 as a four point or greater deterioration 
in the NIHSS within 24 hours after treatment compared with 
the pre-procedure NIHSS attributable to imaging evidence of 
an intracranial hemorrhage as adjudicated by the Core Imaging 
Laboratory. Safety endpoints were adjudicated for severity and 
causality by an independent Clinical Events Committee (CEC). 
All data were monitored during on-site visits.
Secondary efficacy endpoints included good functional neuro-
logical recovery defined as a reduction of 10 or more points in 
the NIHSS or a score of 0–1 at 7 to 10 days' post-procedure, 
times to mTICI ≥2 b revascularization, health economics data, 
and Quality of Life as assessed by EQ-5D-3L score at 90 days 
compared with 7 to 10 days.
statistical analysis
Baseline clinical and imaging data were summarized using 
standard descriptive statistics. This included the number of 
observations, mean, median, SD, minimum and maximum for 
continuous variables, and counts and percentages for discrete 
variables. All confidence intervals presented were two-sided. All 
statistical tests were two-tailed with a significance level of 0.05. 
Analyses were performed using SAS software (version 9.4; SAS 
Institute).28
The primary effectiveness analysis was an unadjusted non-in-
feriority comparison between the ACE68/64 reperfusion cath-
eters Penumbra System group and the IAT group from the MR 
CLEAN trial. For sample size calculation, it was assumed that 
38% (76/200) of the PS patients would experience primary 
endpoint success for 90-day mRS 0–2 compared with 32.6% 
(76/233) of the MR CLEAN IAT group: the estimated difference 
and 95% CI for the difference between groups would therefore 
be 5.4% (-3.7%, 14.4%). As the primary analysis, all efficacy and 
safety outcome measures were analyzed under the intent-to-treat 
(ITT) principle.
Prespecified analyses of association between primary and 
selected secondary endpoints (mTICI 2b-3 post-procedure, 
90-day mRS 0–2, device- or procedure-related SAEs at 24 hours 
and 30 days, 90-day mortality, occurrence of sICH) were 
conducted, with adjustment for several baseline characteristics 
(age, baseline NIHSS, occlusion location).
resulTs
baseline patient data
Between February 2016 and May 2017, the PROMISE study 
enrolled 204 patients across 20 European centers using ADAPT 
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Table 1 Baseline and procedural characteristics
Characteristic Patients (n)
Age, years 71.3±12.4 (204) (mean±SD)
74/65–80 (median/IQR)
Female 61.8% (126/204)
Baseline NIHSS 15.4±5.8 (204) (mean±SD)
16/11–20 (median/IQR)
  < 16 46.6 % (95/204) 
  16 – 20 32.8 % (67/204) 
  > 20 20.6 % (42/204) 
CT ASPECTS*: per site assessment 8.7±1.2 (173) (mean±SD)
9/8–10 (median/IQR)
MR DWI ASPECTS: per site assessment 7.4±1.5 (30) (mean±SD)
8/6–8 (median/IQR)
IV rt-PA administered prior to procedure 61.8% (126/204)
Time from symptom onset to hospital admission 
(min)
115.3±78.6 (204) (mean±SD)
97.0/58.5–154.5 (median/IQR)
Site of vessel occlusion
Internal carotid artery/carotid T 21.1% (43/204)
Middle cerebral artery 78.9 % (161/204) 
First segment (M1) 60.8% (124/204)
Second segment (M2) 18.1% (37/204)
Procedural information
Penumbra ACe Catheters, (% n/n) All patients (n=204)
Frontline device 
  ACE68 65.7 % (134/204) 
  ACE64 32.8 % (67/204) 
Other Penumbra catheters: 3MAX, 5MAX, ACE 60 1.5% (3/204)†
Frontline ACE68/64 catheter passes 1.6±0.9 (201) (mean±SD (N))
1/1–2 (median/IQR)
Additional mechanical intervention (% n/n)‡ ACe 68/64 PATIenTs n=201
Stent retriever after Penumbra System, total 20.9 % (42/201)
  Target vessel/remaining clot 13.4 % (27/201) 
  Distal vasculature 9% (18/201)
Stent for proximal stenosis or dissection 2% (4/201)
Balloon angioplasty for proximal stenosis 2% (4/201)
Catheter from other manufacturer 1% (2/201)
Data are % (n/N) or mean ±SD (N) (median) (IQR). ASPECTS, Alberta Stroke Program 
Early CT Score; IQR, interquartile range; NIHSS, National Institutes of Health Stroke 
Scale; mRS, modified Rankin Scale.
*One patient with ASPECTS score not available due to a previous stroke. Principal 
Investigator confirmed the inclusion of the patient.
†Three patients were treated with ACE60, 3MAX, or 5MAX, admitted under protocol 
version B.
‡Patients may have more than one additional mechanical intervention.
with the Penumbra System and ACE68/64 catheters as frontline 
treatment. For enrollment, 30 (14.7%) patients were selected by 
MRI and 174 (85.3%) by CT. Of the 1433 patients screened 
and documented in site-specific Screening and Enrollment Logs, 
1229 patients (85.8%) were screen failures and 204 patients 
(14.2%) were enrolled. The five most common reasons for 
screen failure were no imaging evidence of LVO of the ante-
rior circulation (22.1%, 271/1229), followed by unknown onset 
of stroke symptoms with last proof of good health more than 
6 hours before (10.3%, 126/1229), lack of possibility to obtain 
informed consent (10.2%, 125/1229), onset of stroke symp-
toms >6 hours (8.2%, 101/1229) or angiographic evidence of 
tandem extracranial occlusion or arterial stenosis proximal to 
occlusion requiring treatment prior to thrombus removal (8.2%, 
101/1229). Four patients withdrew consent prior to the 90-day 
visit, therefore, 200 patients completed the 90-day visit and 
were included in the follow-up analysis.
Baseline characteristics are displayed in table 1. The median 
age was 74 years, ranging from 27 to 96 years, and almost 
two-thirds of the patients were women (61.8%). Thirty-five 
percent (35.3%) of patients were transferred from other hospi-
tals, 79.9% of stroke onsets were witnessed, and 20.1% of 
patients were last known to be well within 6 hours before inclu-
sion without knowing the exact time of onset. The median time 
from stroke onset to hospital admission was 97 min (IQR 58.5–
154.5). The median baseline NIHSS score was 16 (IQR 11–20) 
and ranged from 2 to 36. At admission, the median CT ASPECTS 
was 9, while the median MRI DWI ASPECTS was 8. Occlusions 
were located in the ICA/carotid T (21.1%) and MCA (78.9%; 
60.8% in M1, 18.1% in M2) and IV rt-PA was administered in 
126 patients (61.8%), mainly within a bridging protocol 86.5% 
(109/126). At baseline, mTICI was 0 in most patients (91.2%, 
186/204) with mTICI 1 in 8.3% (17/204) of patients.
The ACE68 catheter was utilized as frontline treatment in 
65.7% of patients and the ACE64 in 32.8%: three patients 
(1.5%) were initially treated with other PS devices (table 1). For 
cases that required adjunctive therapy, the median number of 
ACE68/64 passes performed before switching was 2 (IQR 1–3). 
General anesthesia was performed in 58.3%, conscious sedation 
in 18.1%, and local anesthesia only in 23.5% of patients. A stent 
was placed for proximal stenosis or dissection in 2% of patients, 
and balloon angioplasty was used for proximal stenosis in 2% of 
patients. In 20.9% of patients, a stent retriever was used after PS 
as adjunctive treatment, in 13.4% of cases at the target vessel, 
9% in distal vasculature, and 1.5% in both. No balloon guide 
catheters were reported to be used.
Primary outcomes
The proportion of patients with Core Laboratory-assessed 
mTICI 2b-3 was 93.1% (190/204) after all treatment (39.2% 
mTICI 3, 53.9% mTICI 2b). After Penumbra System treatment 
alone, 70.6% (144/204) of patients achieved mTICI 2b-3. Out 
of all patients achieving mTICI 2b-3 after ACE68/64, 74.4% 
(90/121) achieved revascularization after the first ACE68/64 
pass. At 90 days, 61% of patients (122/200) achieved good func-
tional outcome (mRS 0–2) (table 2). The study met its primary 
effectiveness endpoint (Online Supplement).
secondary outcomes
Regarding safety endpoints, the all-cause mortality and morbidity 
rates at 90 days were 7.5% (15/200) and 31.5% (63/200), respec-
tively, and the 24-hours sICH rate was 2.9% (6/204). According 
to MedDRA preferred terms, three patients died due to progres-
sion of stroke, two patients died due to cerebrovascular accident, 
and the remaining 10 patients died due to different causes (cere-
bral hemorrhage, hemorrhagic transformation stroke, ischemic 
stroke, seven others not related to stroke). The ENT rate was 
1.5% (3/204), vessel perforation rate was 0.5% (1/204), distal 
emboli rate was 1.0% (2/204), and vessel dissection rate was 
2.5% (5/204) (table 2). The frequency of new ischemic stroke 
within 24 hours was 0%.
Per adjudication by the CEC, there were nine device- and 
procedure-related SAEs (4.4%) at 30 days, of which seven (3.4%) 
occurred within 24 hours. These events included carotid artery 
dissection (n=2), cerebral artery embolism (n=2), cerebral 
artery occlusion (n=1), cerebral hematoma (n=1), hemorrhagic 
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Table 2 Primary and secondary endpoints
outcome % (n/n)
Primary endpoints
mTICI 2b-3 at post-procedure: per core 
laboratory*
93.1% (190/204)
mRS 0–2 at 90 days† 61% (122/200)
secondary endpoints
Neurologic improvement‡ 67.9% (127/187)
Device-related SAEs at 24 hours: per CEC 1.5% (3/204)
Device-related SAEs at 30 days: per CEC 2.0% (4/204)
Procedure-related SAEs at 24 hours: per CEC 3.4% (7/204)
Procedure-related SAEs at 30 days: per CEC 4.4% (9/204)
All-cause mortality at 90 days§ 7.5% (15/200)
Morbidity at 90 days|| 31.5% (63/200)
Symptomatic intracranial hemorrhage at 
24 hours: per CEC#
2.9% (6/204)
Embolization of new territory: per CEC 1.5% (3/204)
Vessel damage: per CEC 2.9 % (6/204) 
  Vessel perforation 0.5 % (1/204) 
  Vessel dissection 2.5% (5/204)
Symptom onset to ASPECTS CT/MRI, minutes 137.9±71.0 (204) (mean±SD)
127.5/81.5–188.0 (median/IQR)
Imaging to arterial puncture, minutes 72.2±44.2 (204) (mean±SD)
61.5/41.0–91.5 (median/IQR)
Arterial puncture to revascularization, minutes 40.1±27.2 (204) (mean±SD)
31.0/20.0–53.0 (median/IQR)
EQ-5D-3L VAS improvement at 90 days 
compared with 7–10 days
4.7±20.4 (119) (mean±SD)
5/0–15 (median/IQR)
Data are % (n/N) or mean ±SD (N) (median) (IQR). ASPECTS, Alberta Stroke Program 
Early CT Score; CEC, Clinical Events Committee; CI, confidence interval; IQR, 
interquartile range; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in 
Cerebral Infarction; SAE, serious adverse event.
*For two patients missing Core Laboratory DSA review due to vessel not visualized, 
PI assessment of mTICI score carried over.
†Four patients withdrew prior to the 90-day follow-up and were excluded from 
90-day mRS analysis.
‡Good functional neurological recovery defined as a reduction of 10 or more points 
in the median NIHSS or a score of 0–1 at 7–10 days. Seventeen patients did not 
have 7–10 day NIHSS assessment.
§Mortality assigned as 90-day mRS 6.
¶Morbidity defined as 90-day mRS 3–5.
**Defined as 24 hours CT evidence of an ECASS-defined intracranial hemorrhage 
associated with a 4-point or more worsening of the NIHSS score.
Figure 1 Comparison of PROMISE time metrics with MR CLEAN, 
STRATIS, and ASTER trials (A) MR CLEAN and PROMISE procedural time 
comparison. (B) STRATIS and PROMISE procedural time comparison. (C) 
ASTER and PROMISE procedural time comparison.
cerebral infarction (n=1), subarachnoid hemorrhage (n=1), 
and vascular pseudoaneurysm (n=1). Regarding vessel damage 
events (serious and non-serious), there were five arterial dissec-
tions, all of which were extracranial, and one perforation during 
stent retriever use in distal vasculature. Four of the five dissec-
tions were unrelated to ACE catheter use and possibly/probably/
definitely related to the procedure.
Regarding secondary efficacy endpoints, good functional 
neurological recovery was achieved in 67.9% of patients 
(127/187), with 35.3% (66/187) having NIHSS 0–1. The times 
to revascularization endpoint data are shown in table 2. The 
median reperfusion time (arterial access to mTICI 2b-3 or final 
angiogram if 2b-3 was not achieved) was 31 min (IQR 20–53), 
and the median time from stroke onset to mTICI 2b-3 or final 
angiogram was 245.5 min (IQR 192–305). The current time 
metrics are shown in figure 1. Please see Online Supplement for 
details of safety events, primary effectiveness analysis, and addi-
tional process times.
Self-reported assessment on quality of life at 90 days compared 
with 7 to 10 days included improvement in mobility (9.9%), 
self-care (14.5%), usual activities (19.0%), and pain/discomfort 
(7.1%), and worsening in anxiety/depression (4.2%). Median 
duration of index hospitalization was 8 days (IQR 5–11), which 
is typical per European standard of care, and all-cause rehospi-
talization rate from discharge to 90 days was 8.3% (17/204). Of 
note, 73.5% of patients (150/204) were back home by 90 days.
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subgroup analyses
In pre-specified subgroup analyses of primary and selected 
secondary endpoints, several baseline covariates were examined 
including stroke severity per NIHSS (<16, 16–20, or >20), age 
(<80 or≥80 years), and occlusion location. In unadjusted anal-
ysis, lower baseline NIHSS and younger age (<80 years) were 
predictors of functional independence. In addition, younger age 
(<80 years) was a predictor of decreased mortality. No impact of 
higher baseline NIHSS on the occurrence of sICH or mortality 
was observed. In analysis adjusted for the significant predictors 
of baseline or outcome differences, there were no differences 
in rates of 90-day mRS 0–2, mTICI 2b-3, or mortality between 
transfer and direct-admit patients. For subgroup analysis details, 
please see Online Supplement.
dIsCussIon
Results from the PROMISE study supported the safety and effec-
tiveness of the ACE68 and ACE64 reperfusion catheters with 
the PS in patients with AIS secondary to anterior LVO, using 
the ADAPT technique as frontline therapy in real-world prac-
tice. mTICI 2b-3 post-procedure was achieved in 93.1% of cases 
(including 20.9% of patients who were also treated with stent-re-
trievers), and 61% of cases achieved 90-day mRS 0–2. The 
median time from arterial puncture to mTICI 2b-3 was 31  min. 
The safety profile was favorable with 7.5% early mortality, 2.9% 
sICH, and 1.5% ENT rates.
In the ASTER RCT which randomly assigned patients to a 
frontline approach with contact aspiration or stent retriever, 
therapy with the ADAPT technique was not superior to 
stent retrievers in safety or efficacy.16 A recent meta-analysis 
(HERMES) pooled patient-level data from five RCTs comparing 
endovascular thrombectomy to standard medical care in patients 
with AIS. It showed the benefit of mechanical thrombectomy 
devices over medical management alone.7 The STRATIS study 
determined that outcomes observed in a meta-analysis (SEER 
Collaboration) pooling patient-level data from four RCTs could 
be reproduced in a large real-world cohort.15
Data from the current study were compared with published 
literature. Compared with ASTER, mTICI 2b-3 was achieved in 
93.1% of patients in PROMISE (20.9% stent retriever use) vs 
85.4% in ASTER (32.8% stent retriever use). Compared with 
the endovascular treatment groups in HERMES, STRATIS, and 
ASTER, the proportion of patients with 90-day mRS scores 0–2 
was higher in PROMISE (61% vs 46% in HERMES, 56.5% in 
STRATIS, and 45.3% in ASTER aspiration). Age and baseline 
NIHSS in these trials were comparable to the PROMISE popu-
lation, although other characteristics, such as tandem occlusion, 
may vary. The 90-day mortality rate was satisfactory in PROMISE 
(7.5% vs 15.3% in HERMES, 14.4% in STRATIS, 19.3% in 
ASTER aspiration). The rate of sICH in PROMISE was lower 
than HERMES and ASTER and higher than STRATIS (2.9% vs 
4.4% in HERMES, 1.4% in STRATIS, 5.3% in ASTER aspira-
tion). The rate of ENT observed in PROMISE was lower than 
ASTER and higher than STRATIS (1.5% vs 0.8% in STRATIS, 
3.7% in ASTER aspiration). It should be noted that ASTER used 
almost exclusively ACE64 and 5MAX catheters over ACE68 (65 
ACE64, 1 ACE68, 63 5MAX devices were used frontline in the 
aspiration group).
The improvement in revascularization rates observed in 
PROMISE might be due to the introduction of the ACE68/64 
catheters, along with improved technical skills due to the 
higher volume of endovascular treatment in recent years. On 
the other hand, improvements of in-hospital processing times 
implemented after the introduction of new stroke treatment 
guidelines8–10 as seen in the rapid symptom onset to arterial 
puncture time (comparison with MR CLEAN, STRATIS, and 
ASTER in figure 1) might also be correlated with better patient 
outcomes observed in PROMISE. These observations suggest 
that the ADAPT technique is an effective method, and that the 
rate of complications, especially of sICH, is low. This favorable 
safety profile may arise from the use of the recently introduced 
large-bore catheters with improved trackability, resulting in less 
manipulation with multiple devices. Though not a prespecified 
analysis, no significant differences in safety or effectiveness 
outcomes were noted between the two catheter groups, ACE64 
or ACE68. There were no differences in baseline patient char-
acteristics, except for more cardiac heart failure, less peripheral 
artery disease, and higher pre-stroke mRS >0, in the ACE68 
group. The first-pass success rate with ADAPT was 60.2%, 
with no significant difference between catheter sizes (58.2% vs 
61.2%, ACE64 vs ACE68). Outcomes should be evaluated with 
caution due to the unknown impact of the baseline covariates. 
The potential impact of catheter size remains to be elucidated 
in a larger study with a matched patient population. In the 
PROMISE study, balloon guide catheters were not used due to 
lesional aspiration at the proximal face of the clot.
The primary limitation of the PROMISE study was inherent 
in its study design and lack of a randomized controlled compar-
ison, and the absence of blinding of the 3- month mRS assess-
ment. Although PROMISE study criteria excluded patients 
with tandem lesions requiring treatment prior to aspiration, 
nine patients (4.4%) with proximal stenosis were enrolled and 
five required intervention (two stenting and angioplasty, one 
stenting, and two angioplasty alone), which may be a lower 
proportion compared with other studies. The major strengths 
of this study include evaluation by an independent Core Labora-
tory and a Clinical Events Committee, prospective and consecu-
tive enrollment of patients to minimize potential bias associated 
with a registry, all data being monitored during on-site visits, and 
data collected from real-world clinical practice across Europe.
suMMAry
As technical and clinical developments in stroke treatment evolve, 
these results suggest that in current practice, the ADAPT tech-
nique with ACE68/ACE64 offers equal or better results compared 
with other techniques. The findings from the PROMISE study 
support the use of aspiration with ACE68/ACE64 reperfusion 
catheters as a frontline therapy in the treatment of patients with 
ischemic stroke from large vessel occlusion.
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